Navigation Links
BioMarin to Present at the Wedbush Life Sciences Conference
Date:8/9/2011

NOVATO, Calif., Aug. 9, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 2011 at 10:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical developmen
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin Announces Second Quarter 2011 Financial Results
2. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
3. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
4. BioMarin to Present at the William Blair Growth Stock Conference
5. BioMarin to Present at the Jefferies Global Healthcare Conference
6. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
7. BioMarin Announces First Quarter 2011 Financial Results
8. BioMarin to Present at the Deutsche Bank Healthcare Conference
9. BioMarin to Present at the Barclays Global Healthcare Conference
10. BioMarin to Present at the Cowen Health Care Conference
11. BioMarin to Present at the Citi Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Corporation (NASDAQ: TECH ) announced today that ... new Simple Plex platform through its Proteins Platform division ... of the previously acquired CyPlex instrument platform from CyVek. ... immunoassay technology which integrates an innovatively designed microfluidic cartridge ...
(Date:1/22/2015)... PARK, Calif. , Jan. 22, 2015 Increasing ... the continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research ... chose a single-source solution for their translation and localization ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Microbiology Testing/Clinical Microbiology Market ... Global Forecast to 2019" report to their ... wide array of techniques for the detection of ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Corporation (Nasdaq: DRRX ) today reported that King ... Inc. (Nasdaq: PTIE ) have announced that King ... the U.S. Food and Drug Administration (FDA) in response to ... 2008.  This is a Class 2 resubmission with a six ...
... During ICMS (International Cellular Medicine Society www.cellmedicinesociety.org ) ... Conference held on November 12, 2010 in Las Vegas, ... of diabetes gangrene recovered from foot ulcer through stem ... ) Patient, Sun Rae Cho (age 72 ...
Cached Medicine Technology:REMOXY® New Drug Application Resubmitted 2REMOXY® New Drug Application Resubmitted 3New Hope for Saving Diabetic Foot from Amputation 2
(Date:1/22/2015)... Nashville, TN (PRWEB) January 22, 2015 Gabe’s Chemo ... Chemo Duck App, the first app ever created for kids with ... all Apple phones and devices, is filled with enjoyable games to ... life and treatments. The free app helps to keep kids entertained, ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... , FRIDAY, Sept. 23 (HealthDay News) -- Many studies have ... day is heart-healthy, and much of the benefit has been ... wine called polyphenols. But a new Dutch study suggests ... lower blood pressure after all. Study author Ilse ...
... the longest-running trial comparing tamoxifen with the aromatase ... the test of time and continues to prevent ... death in post-menopausal women with hormone receptor-positive early ... at the 2011 European Multidisciplinary Cancer Congress [1], ...
... obesity, has been linked to the development of asthma in ... at the European Respiratory Society,s Annual Congress in Amsterdam today ... factor for the disease. Excess abdominal fat has been ... and heart disease, but there has been little focus on ...
... Stockholm, Sweden: Many prostate cancer patients develop bone metastases, ... Now the first large randomised Phase III trial of ... a single dose of the drug is as good ... treatment for bone metastases. Results of the trial were ...
... the devastating personal and financial impact that chronic obstructive ... The findings, which are to be presented today ... Congress in Amsterdam, provides new perspectives on the personal ... 45-65 year age group. 80% reported ...
... Stockholm, Sweden: The first randomised trial to investigate the ... for the initial treatment of HER2- (human epidermal ... that it makes a significant difference to the time ... Hurvitz, one of the trial investigators, will tell the ...
Cached Medicine News:Health News:Antioxidants Not Behind Red Wine's Healthy Effect on Heart: Study 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 3Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 4Health News:'Belly fat' linked to development of asthma 2Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 2Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 3Health News:Study sheds light on the impact of COPD on working aged populations 2Health News:Phase II study shows new cancer drug combination significantly delays breast cancer progression 2Health News:Phase II study shows new cancer drug combination significantly delays breast cancer progression 3
The Link SP II Hip stem for cemented revisions...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Quatroloc Revision Hip System...
Severe revision options for the knee and hip...
Medicine Products: